Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma
/PRNewswire/ -- Henlius (2696.HK) announced its 2022 interim results. As a global innovative biopharmaceutical company, Henlius is committed to offering...
Source: prnewswire.com